

**REMARKS**Claim Amendments

Claim 18 has been canceled.

Claim 17 has been amended to provide proper dependency.

Accordingly, claims 1-6, 9-15, 17, 21-23, 26-36, and 38-43 are pending.

Attached hereto is a marked-up version of the amendments made to the claims by the current amendment. The attached page is captioned "Version with Markings to show changes made." Also attached hereto is a copy of the pending claims. The attached page is captioned "Pending Claims." No new matter has been added.


Restriction Requirement

Applicants reiterate their election of the single *Lol p* V peptide, LPIX-4 (SEQ ID NO:6) and the first peptide mixture in claim 22 (LPIX-4 (SEQ ID NO:6), LPIX-5 (SEQ ID NO:7), LPIX-6 (SEQ ID NO:8), LPIX-16 (SEQ ID NO:18), LPIX-17 (SEQ ID NO:19), and LPIX-20 (SEQ ID NO:22)) without traverse. Further, it is noted that claims 1-6, 9, 12-15, 17, 21-23, 26-36, 42, and 43 are readable on the elected species.

**SUMMARY**

If a telephone conversation with Applicants' attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' attorney at (617) 227-7400.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

  
Jeanne M. DiGiorgio  
Registration No. 41,710  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
Tel. (617) 227-7400

Dated: 10 July 02

**Version with Markings to Show Changes Made****In the Claims**

Claim 18 has been canceled.

Claim 17 has been amended as follows:

17. (Amended) An isolated peptide produced in a host cell transformed with ~~the~~ a nucleic acid of claim 7 comprising a portion of the nucleotide sequence shown in SEQ ID NO:1.